TY - JOUR
T1 - Averting multiple sclerosis long-term societal and healthcare costs
T2 - The Value of Treatment (VoT) project
AU - Tinelli, Michela
AU - Pugliatti, Maura
AU - Antonovici, Andreea
AU - Hausmann, Bettina
AU - Hellwig, Kerstin
AU - Quoidbach, Vinciane
AU - Sørensen, Per Soelberg
N1 - Copyright © 2021. Published by Elsevier B.V.
PY - 2021/9
Y1 - 2021/9
N2 - BACKGROUND AND PURPOSE: The recent report on Value-of-Treatment (VoT) project highlights the need for early diagnosis-intervention, integrated, seamless care underpinning timely care pathways and access to best treatments. The VoT-multiple-sclerosis (MS) economic case study analysis aimed to estimate the effectiveness/cost-effectiveness of both early treatment and reducing MS risk factors (e.g. smoking and vitamin D insufficiency).METHODS: A series of decision analytical modellings were developed and applied to estimate the cost-effectiveness of: (1) reducing the conversion from clinically-isolated-syndrome (CIS) to clinically-definite-MS (CDMS); (2) smoking cessation and increase of 25 hydroxyvitamin D (25(OH)D) serum level. Both (1) and (2) considered socioeconomic impact on averted MS disability progression. Costs were reported for societal and healthcare provider perspectives (pending on data across nations; Euros). Effectiveness was expressed as Quality-Adjusted-Life-Years (QALYs) gains. Long term (25, 30, 40,50-years) and short (one-year) timelines were considered for (1) and (2), respectively.RESULTS: Early treatment was cost-effective for the health care provider and both cost-effective/cost-saving for the society across time-horizons and nations. Smoking cessation and an increase of 25(OH)D in MS patients were both cost-effective/cost-saving across nations.CONCLUSIONS: To the best of our knowledge, our work provides the first economic evidence to base appropriate public health interventions to reduce the MS burden in Europe.
AB - BACKGROUND AND PURPOSE: The recent report on Value-of-Treatment (VoT) project highlights the need for early diagnosis-intervention, integrated, seamless care underpinning timely care pathways and access to best treatments. The VoT-multiple-sclerosis (MS) economic case study analysis aimed to estimate the effectiveness/cost-effectiveness of both early treatment and reducing MS risk factors (e.g. smoking and vitamin D insufficiency).METHODS: A series of decision analytical modellings were developed and applied to estimate the cost-effectiveness of: (1) reducing the conversion from clinically-isolated-syndrome (CIS) to clinically-definite-MS (CDMS); (2) smoking cessation and increase of 25 hydroxyvitamin D (25(OH)D) serum level. Both (1) and (2) considered socioeconomic impact on averted MS disability progression. Costs were reported for societal and healthcare provider perspectives (pending on data across nations; Euros). Effectiveness was expressed as Quality-Adjusted-Life-Years (QALYs) gains. Long term (25, 30, 40,50-years) and short (one-year) timelines were considered for (1) and (2), respectively.RESULTS: Early treatment was cost-effective for the health care provider and both cost-effective/cost-saving for the society across time-horizons and nations. Smoking cessation and an increase of 25(OH)D in MS patients were both cost-effective/cost-saving across nations.CONCLUSIONS: To the best of our knowledge, our work provides the first economic evidence to base appropriate public health interventions to reduce the MS burden in Europe.
KW - Cost-Benefit Analysis
KW - Demyelinating Diseases
KW - Health Care Costs
KW - Humans
KW - Multiple Sclerosis/epidemiology
KW - Quality-Adjusted Life Years
UR - http://www.scopus.com/inward/record.url?scp=85111139513&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2021.103107
DO - 10.1016/j.msard.2021.103107
M3 - Journal article
C2 - 34237560
SN - 2211-0348
VL - 54
SP - 103107
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
M1 - 103107
ER -